Mr. Thomas Smeenk reports
HEMOSTEMIX ANNOUNCES IT IS TRADING ON THE FRANKFURT STOCK EXCHANGE AND IT HAS RETAINED HE CAPITAL MARKETS LTD.
Hemostemix Inc. has begun trading on the Frankfurt Stock Exchange under the symbol 2VF0.F, and it has engaged HE Capital Markets Ltd. to design and implement a North American and European multimedia digital advertising campaign on certain investor-focused and financial market websites. HE Capital will also provide other media communication services to raise the company's overall corporate profile in North America and Europe.
Thomas Smeenk, chief executive officer, said: "With the listing on Frankfurt and the engagement of HE Capital, we are deepening our liquidity pools, introducing Hemostemix to a broader investment community. In the USA [United States of America], we are working to uplist the company, and we are exploring how best to reach our audience in Asia."
The cash consideration to be paid by the company for these services consists of $18,000 (U.S.) for an initial three-month campaign. HE Capital acts at arm's length to Hemostemix and does not currently have any interest, directly or indirectly, in the company or its securities. HE Capital may choose to acquire securities of Hemostemix in the future.
HE Capital is a London-based investor relations and capital market advisory firm, providing comprehensive communication solutions to public-company clients in North America and Europe through a combination of investor relations, public relations, and digital and social media services. HE Capital's office address is 6 Hays Lane, London Bridge, London, SE1 2HB, United Kingdom.
About Hemostemix Inc.
Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum technology pioneer award, the company developed, and is commercializing, its lead product, ACP-01, for the treatment of CLI, PAD, angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On Oct. 21, 2019, the company announced the results from its phase 2 multicentre, randomized, double-blind, placebo-controlled clinical trial of ACP-01 in critical limb ischemia abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup," which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years.
The company owns 91 patents across four patent families titled: regulating stem cells; in vitro techniques for use with stem cells; production from blood of cells of neural lineage; and automated cell therapy.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.